High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

Jacobsen,Frank; Ashtiani,Sharad  Nouraie; Tennstedt,Pierre; Heinzer,Hans; Simon,Ronald; Sauter,Guido; Sirma,Hüseyin; Tsourlakis,Maria  Christina; Minner,Sarah; Schlomm,Thorsten; Michl,Uwe

doi:10.3892/etm.2012.764

January 2013 Volume 5 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January 2013 Volume 5 Issue 1

Full Size Image

Article

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

Authors:
- Frank Jacobsen
- Sharad Nouraie Ashtiani
- Pierre Tennstedt
- Hans Heinzer
- Ronald Simon
- Guido Sauter
- Hüseyin Sirma
- Maria Christina Tsourlakis
- Sarah Minner
- Thorsten Schlomm
- Uwe Michl
View Affiliations / Copyright

Affiliations: Institute of Pathology, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany, Martini-Clinic Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany
Pages: 102-106
|
Published online on: October 25, 2012

https://doi.org/10.3892/etm.2012.764
Expand metrics +

Abstract

c-MET is considered a possible therapeutic target in numerous tumor types and is also a candidate regulator of response to anti-HER2 and anti-epidermal growth factor receptor (EGFR) therapy. The aim of this study was to determine the prevalence and clinical significance of c-MET expression in hormone-naïve prostate cancers. A pre-existing prostate tissue microarray (TMA) containing samples of 4,177 patients treated by radical prostatectomy was used. A total of 3,378 different prostate cancers were successfully analyzed for c-MET expression by immunohistochemistry and follow-up data were available for 4,104 patients. Membranous c-MET immunostaining was performed for 2,655 (78.6%) tumors. High c-MET protein expression was significantly associated with a high Gleason grade (P=0.0018). However, c-MET was not a prognostic marker for biochemical recurrence. c-MET levels were also not associated with other parameters, including tumor stage, nodal stage and surgical margin status. The c-MET protein is often overexpressed in prostate cancer, but has no prognostic relevance. However, the frequent presence of high levels of membranous c-MET protein in prostate cancer cells makes c-MET an attractive target for imaging and treatment.

View Figures

View References

1	Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 311:29–33. 1984. View Article : Google Scholar : PubMed/NCBI
2	Knudsen BS and Edlund M: Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 91:31–67. 2004. View Article : Google Scholar : PubMed/NCBI
3	Peruzzi B and Bottaro DP: Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 12:3657–3660. 2006. View Article : Google Scholar : PubMed/NCBI
4	Kong DS, Song SY, Kim DH, et al: Prognostic significance of c-Met expression in glioblastomas. Cancer. 115:140–148. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and Cho MK: Expression of the c-Met proteins in palignant skin cancers. Ann Dermatol. 23:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
6	De Oliveira AT, Matos D, Logullo AF, et al: MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 29:4807–4811. 2009.PubMed/NCBI
7	Matteucci E, Bendinelli P and Desiderio MA: Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis. 30:937–945. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ichimura E, Maeshima A, Nakajima T and Nakamura T: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res. 87:1063–1069. 1996. View Article : Google Scholar : PubMed/NCBI
9	Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y and Tahara E: Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer. 55:72–75. 1993. View Article : Google Scholar : PubMed/NCBI
10	Belfiore A, Gangemi P, Costantino A, et al: Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab. 82:2322–2328. 1997.PubMed/NCBI
11	Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 147:386–396. 1995.PubMed/NCBI
12	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
13	Knudsen BS, Gmyrek GA, Inra J, et al: High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 60:1113–1117. 2002. View Article : Google Scholar : PubMed/NCBI
14	Watanabe M, Fukutome K, Kato H, et al: Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 141:173–178. 1999. View Article : Google Scholar
15	Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC and Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 154:293–298. 1995. View Article : Google Scholar : PubMed/NCBI
16	Tu WH, Zhu C, Clark C, Christensen JG and Sun Z: Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10:5562010. View Article : Google Scholar : PubMed/NCBI
17	Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ and Gallick GE: The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20:1677–1684. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gross ME, Jo S and Agus DB: Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2:53–56. 642004.PubMed/NCBI
19	Erbersdobler A, Fritz H, Schnöger S, et al: Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol. 41:40–46. 2002. View Article : Google Scholar
20	Bubendorf L: High-throughput microarray technologies: from genomics to clinics. Eur Urol. 40:231–238. 2001. View Article : Google Scholar : PubMed/NCBI
21	Miyamoto M, Ojima H, Iwasaki M, et al: Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 105:131–138. 2011. View Article : Google Scholar : PubMed/NCBI
22	Amemiya H, Menolascino F and Peña A: Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin. 51:369–380. 2010.(In Spanish).
23	Freudlsperger C, Alexander D, Reinert S and Hoffmann J: Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med. 1:69–72. 2010.PubMed/NCBI
24	Previdi S, Abbadessa G, Dalò F, France DS and Broggini M: Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther. 11:214–223. 2012. View Article : Google Scholar : PubMed/NCBI
25	Liu X, Wang Q, Yang G, et al: A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 17:7127–7138. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles